hVIVO #HVO – Consultancy contract signed with Decoy Therapeutics to support development of respiratory antiviral candidates June 1, 2026 – Posted in: hVIVO (HVO)

London, UK – 1 June 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces it has signed a consultancy contract with Decoy Therapeutics (“Decoy”) to support the development of its respiratory antiviral candidates. Decoy is developing a portfolio of Designable Multi-Antiviral (D-MAV) candidates, a new antiviral category designed to address multiple viruses by targeting shared viral mechanisms across multiple respiratory viruses using a single…

Continue reading